Flag of the European Union EU Clinical Trials Register Help

Clinical trials for melanoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    610 result(s) found for: melanoma. Displaying page 9 of 31.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2014-001671-30 Sponsor Protocol Number: 2013-TL-MEL-Th Start Date*: 2015-07-31
    Sponsor Name:Centre Eugène Marquis
    Full Title: Evaluation of cobimetinib + vemurafenib combination treatment in patients with brain metastasis BRAFV600 mutated cutaneous melanoma
    Medical condition: Patients with brain metastasis (BM) from BRAFV600-mutated cutaneous melanoma. Patients will be enrolled into three cohorts: A. Neurologically asymptomatic patients who have not received prior loc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002435-42 Sponsor Protocol Number: STH19290 Start Date*: 2018-01-18
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: DANTE: A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma
    Medical condition: Advanced (unresectable stage III or stage IV (metastatic)) melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068117 Metastatic ocular melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021946-22 Sponsor Protocol Number: DeCOG–MM-PAL11 Start Date*: 2011-04-05
    Sponsor Name:University Hospital Essen
    Full Title: THE IPI – MULTIBASKET TRIAL IN ADVANCED OCULAR MELANOMA: PROSPECTIVE CLINICAL PHASE II MULTIBASKET STUDY IN OCULAR MELANOMA PATIENTS WITH ADVANCED DISEASE
    Medical condition: Histologically proven uveal melanoma Measurable disease according to RECIST in unresectable stage III-IV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068117 Metastatic ocular melanoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001421-10 Sponsor Protocol Number: 4783-08 Start Date*: 2008-09-06
    Sponsor Name:Synta Pharmaceuticals Corp.
    Full Title: A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma
    Medical condition: Stage IV Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Prematurely Ended) GB (Prematurely Ended) CZ (Completed) IT (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000725-30 Sponsor Protocol Number: BAY 43-9006/11538 Start Date*: 2007-11-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II, multi-centre, open-label, uncontrolled study to evaluate the efficacy and safety of BAY 43-9006 given daily in combination with repeated 21-day cycles of dacarbazine (DTIC) chemotherapy...
    Medical condition: Subjects with advanced, metastatic, histologically confirmed melanoma, for whom treatment with dacarbazine is considered medically acceptable. Subjects should have measurable and evaluable disease ...
    Disease: Version SOC Term Classification Code Term Level
    10027481
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000132-25 Sponsor Protocol Number: CA224-083 Start Date*: 2020-10-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic ...
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002454-36 Sponsor Protocol Number: 2125-MEL-301 Start Date*: 2018-04-28
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
    Medical condition: Refractory melanoma is a malignant tumor of melanocytes which originates predominantly from skin.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006366-29 Sponsor Protocol Number: IRST172.01 Start Date*: 2009-04-07
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: IMMUNOTHERAPY OF MAINTENANCE IN THE PATIENTS WITH METASTATIC MELANOMA, CLINICAL BENEFIT AFTER CHEMOTHERAPY
    Medical condition: There is a preclinical and clinical rational that supports a synergic effect of the combination of IL-2, RA and PEG-IFN. Maintenance therapy prolongs time to progression. It is also to note the lo...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000552-33 Sponsor Protocol Number: LUMC_2012 Start Date*: 2012-11-27
    Sponsor Name:Leiden University Medical Center
    Full Title: Adoptive T cell therapy plus vaccination in metastatic melanoma patients
    Medical condition: Metastasized melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001918-25 Sponsor Protocol Number: 111714 Start Date*: 2009-01-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open Phase I/II study of immunization with the recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic in association with dacarbazine in patients with MAGE-A3 positive unresectable and prog...
    Medical condition: Patients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005406-54 Sponsor Protocol Number: M14TIL Start Date*: 2014-05-09
    Sponsor Name:Antoni van Leeuwenhoek ziekenhuis
    Full Title: Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab...
    Medical condition: Patients with unresectable and metastatic (stage IIIc and stage IV) melanoma will be randomized to either treatment arm A (ipilimumab) or treatment arm B (TIL) after metastasectomy and feasibility ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000564-29 Sponsor Protocol Number: SUGBG-013001 Start Date*: 2013-04-25
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
    Medical condition: Uveal melanoma liver metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000610-38 Sponsor Protocol Number: CPDR001J2201 Start Date*: 2018-10-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
    Medical condition: Unresectable or metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001974-33 Sponsor Protocol Number: 08/014 Start Date*: 2009-04-14
    Sponsor Name:Radboud University Nijmegen Medical Centre [...]
    1. Radboud University Nijmegen Medical Centre
    2. Rotterdam Eye Hospital
    Full Title: mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients
    Medical condition: Our study population consists of HLA-A2.1 positive patients with a high risk uveal melanoma (stage II) with proven expression of melanoma associated antigens tyrosinase and/or gp100. Patients are i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023058-35 Sponsor Protocol Number: UZB-VUB-10-001 Start Date*: 2011-01-04
    Sponsor Name:UZ BRUSSEL
    Full Title: A Two-Stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination with Ipilimumab in Patients with Previously Treated Unresectable Stage III or IV Melanoma
    Medical condition: Previously Treated Unresectable Stage III or IV Melanoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025670 Malignant melanoma stage III LLT
    12.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003452-21 Sponsor Protocol Number: BRF117277 Start Date*: 2014-01-27
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain.
    Medical condition: Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003273-28 Sponsor Protocol Number: Derm-NCT001 Start Date*: 2012-01-10
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Med Faculty represented by Universitätsklinikum Heidelberg and its Commercial D
    Full Title: Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil: A Pilot Trial for “Proof of Principle”
    Medical condition: Previously treated metastatic melanoma in stage IV or III unresectable
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000416-91 Sponsor Protocol Number: CA186001 Start Date*: 2007-07-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or Locally Advanced Solid Malignanci...
    Medical condition: Patients with Metastatic or Locally Advanced Solid Malignancies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025650 Malignant melanoma LLT
    9.1 10038395 Renal carcinoma LLT
    9.1 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002026-75 Sponsor Protocol Number: UV1-202 Start Date*: 2020-02-18
    Sponsor Name:Ultimovacs ASA
    Full Title: A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment...
    Medical condition: Unresectable or Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020228-23 Sponsor Protocol Number: NL32381.000.10 Start Date*: 2010-12-21
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Immunochemotherapy: Do platin-based chemotherapeutics enhance dendritic cell vaccine efficay in melanoma patients?
    Medical condition: Our study population consists of melanoma patients, with proven expression of melanoma associated tumor antigens gp100 and tyrosinase. Melanoma patients with regional lymph node metastasis in whom ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 07:51:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA